Read by QxMD icon Read


Sudaporn Wongwan, Gerhard K E Scriba
A CD-modified microemulsion electrokinetic chromatography method has been developed and validated for dexamphetamine sulfate which allows the simultaneous determination of charged and uncharged impurities of the drug including the levorotary (R)-enantiomer. The optimized background electrolyte consisted of 1.5% w/w SDS, 0.5% w/w ethyl acetate, 3.5% w/w 1-butanol, 2.5% w/w 2-propanol and 92% w/w 50 mM sodium phosphate buffer, pH 3.0, containing 5.5% w/w sulfated β-CD. Separations were performed in a 50...
September 2010: Electrophoresis
Sudaporn Wongwan, Bunleu Sungthong, Gerhard K E Scriba
A CE assay for the simultaneous determination of charged and uncharged potential impurities (1S,2S-(+)-norpseudoephedrine, 1R,2S-(-)-norephedrine, phenylacetone and phenylacetone oxime) of dexamphetamine sulfate including the stereoisomer levoamphetamine was developed and validated. The optimized background electrolyte consisted of a 50 mM sodium phosphate buffer, pH 3.0, containing 80 mg/mL sulfobutylether-beta-CD and 25 mg/mL sulfated beta-CD. Separations were performed in 40.2/35 cm, 50 mum id fused-silica capillaries at a temperature of 20 degrees C and an applied voltage of -10 kV...
May 2010: Electrophoresis
Nino G Kokiashvili, Sudaporn Wongwan, Carina Landgraf, Kristin Michaelis, Manuela Hammitzsch-Wiedemann, Gerhard K E Scriba
A capillary electrophoresis method for the simultaneous determination of the enantiomeric purity of dexamphetamine as well as the analysis of 1R,2S-(-)-norephedrine and 1S,2S-(+)-norpseudoephedrine as potential impurities has been developed and validated. Heptakis-(2,3-di-O-acetyl-6-O-sulfo)-beta-cyclodextrin was chosen as chiral selector upon a screening of neutral and charged cyclodextrin derivatives. Separation of the analytes was achieved in a fused-silica capillary at 20 degrees C using an applied voltage of 25 kV...
December 5, 2009: Journal of Pharmaceutical and Biomedical Analysis
Susan B Clausen, Stephanie C Read, Simon J Tulloch
OBJECTIVES: Assess the bioavailability of mixed amphetamine salts extended-release (MAS XR) 30-mg capsules and the dose proportionality of pharmacokinetic measures for MAS XR 20, 40, and 60 mg. METHODS: Study A, an open-label single-period study, and Study B, a randomized, open-label, three-way crossover study, were conducted in healthy adults in a clinical research unit. In Study A, 20 subjects received a single MAS XR 30-mg capsule by mouth daily for 7 days. In Study B, 12 subjects received single oral doses of MAS XR 20, 40, and 60 mg separated by 7-14-day washout periods...
December 2005: CNS Spectrums
Richard H Weisler
Stimulant medications have proven to be effective in reducing the core symptoms of hyperactivity, impulsivity and inattention and are considered the first line of therapy for patients with attention-deficit/hyperactivity disorder (ADHD). Mixed amphetamine salts extended-release capsules (MAS XR; Adderall XR, Shire Pharmaceuticals Group) include immediate-release pellets of mixed amphetamine salts that release the first half of the dose upon ingestion and delayed-release pellets that begin to release active drug approximately 4 h later...
June 2005: Expert Opinion on Pharmacotherapy
James J McGough, Joseph Biederman, Laurence L Greenhill, James T McCracken, Thomas J Spencer, Kelly Posner, Sharon Wigal, Jeffrey Gornbein, Simon Tulloch, James M Swanson
OBJECTIVE: To assess the pharmacokinetic (PK) properties of a single daily dose of Adderall (mixed amphetamine salts) and the extended-release formulation, SLI381 (ADDERALL XR), in pediatric attention-deficit/hyperactivity disorder (ADHD). METHOD: Fifty-one children (aged 6-12 years) with ADHD participated in a 6-week, seven-visit, PK and pharmacodynamic study. PK sampling occurred during visit 1 and again at visit 7. At visit 1, subjects received an initial oral dose of SLI381, 20 mg...
June 2003: Journal of the American Academy of Child and Adolescent Psychiatry
Cindy D Stowe, Stephanie F Gardner, Charles C Gist, Eldon G Schulz, Thomas G Wells
OBJECTIVE: To determine whether cardiac indices are altered as assessed by 24-hour ambulatory blood pressure monitoring (ABPM) in male children receiving either chronic methylphenidate or dextroamphetamine/levoamphetamine (Adderall) therapy. METHODS: Boys 7-11 years old who were receiving methylphenidate or Adderall for a minimum of 2 months were asked to participate. Subjects wore ambulatory blood pressure monitors for 24-hour periods both off and on stimulant therapy...
July 2002: Annals of Pharmacotherapy
J Justice, T C Kupiec, P Matthews, P Cardona
The short-term stability of Adderall in three extemporaneously compounded oral liquids was studied. Three suspensions of Adderall 1 mg/mL were prepared from commercially available 10-mg Adderall tablets with Ora-Sweet, Ora-Plus, and a 1:1 mixture of Ora-Sweet and Ora-Plus. Each suspension was stored in the dark in a stability chamber at 25 degrees C and 60% relative humidity for 30 days. The stability of the active drug (a mixture of levoamphetamine and dextroamphetamine salts) in each of the three vehicles was determined immediately after preparation and at 10, 20, and 30 days by using gas chromatography-mass spectrometry (GCMS)...
August 1, 2001: American Journal of Health-system Pharmacy: AJHP
T Spencer, J Biederman, T Wilens, S Faraone, J Prince, K Gerard, R Doyle, A Parekh, J Kagan, S K Bearman
BACKGROUND: We report on a controlled trial of a mixed amphetamine salts compound (Adderall, dextroamphetamine sulfate, dextro-, levoamphetamine sulfate, dextroamphetamine aspartate, levoamphetamine aspartate, and dextroamphetamine saccharate) in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). METHODS: This was a 7-week, randomized, double-blind, placebo-controlled, crossover study of Adderall in 27 well-characterized adults satisfying full DSM-IV criteria for ADHD of childhood onset and persistent symptoms into adulthood...
August 2001: Archives of General Psychiatry
I Mahmood
Selegiline is a selective inhibitor of monoamine oxidase-B (MAO-B) at a dose of 10 mg/day and is given to patients with Parkinson's disease as an adjunct to levodopa therapy. By inhibiting MAO-B, selegiline increases the dopamine levels in the substantia nigra. Selegiline also blocks dopamine re-uptake from the synaptic cleft, thus increasing the dopamine concentrations in the brain. At a dose of 10 mg/day, selegiline is devoid of 'cheese effect'. The pharmacokinetics of selegiline are highly variable. Following an oral dose of selegiline 10 mg, it is rapidly absorbed and metabolised to desmethylselegiline, levoamphetamine and levomethamphetamine...
August 1997: Clinical Pharmacokinetics
E H Heinonen, M I Anttila, H L Karnani, L M Nyman, J A Vuorinen, K A Pyykkö, R A Lammintausta
Selegiline, an irreversible and selective inhibitor of monoamine oxidase type B (MAO-B), is metabolized into desmethylselegiline, levomethamphetamine, and levoamphetamine. In animal experiments, desmethylselegiline also has been shown to be an irreversible inhibitor of MAO-B. This study investigated the inhibitory potential of MAO-B and the pharmacokinetics of desmethylselegiline in humans. A double-blind, crossover trial was performed to compare the effects of a single dose (10 mg) of selegiline or desmethylselegiline on MAO-B platelet activity...
July 1997: Journal of Clinical Pharmacology
I W Wainer, L C Schneider, J D Weber
Optically pure d- and l-amphetamine sulfate, as well as various mixtures of the 2 enantiomers, were analyzed using a europium chiral nuclear magnetic resonance shift reagent. The enantiomeric shift difference (delta delta delta) exhibited by the doublet associated with the alpha-methyl protons was large enough to differentiate between the levo- and dextro-isomers. The alpha-methyl protons were decoupled and the enantiomeric composition was determined by using the peak heights of the resulting singlets. As little as 5% of the levo-isomer in the presence of the dextro-isomer can be determined using this method...
July 1981: Journal—Association of Official Analytical Chemists
L E Arnold, V Kirilcuk, S A Corson, E O Corson
No abstract text is available yet for this article.
February 1973: American Journal of Psychiatry
L E Arnold, P H Wender, K McCloskey, S H Snyder
No abstract text is available yet for this article.
December 1972: Archives of General Psychiatry
J D Parkes, D Tarsy, C D Marsden, K T Bovill, J A Phipps, P Rose, P Asselman
Twenty-two patients with Parkinsonism were treated with levoamphetamine and 12 of these with dextroamphetamine. Levoamphetamine resulted in a significant improvement in disability from Parkinsonism, although the reduction in total disability, tremor, akinesia, and rigidity scores was slight (ca 20 percent). Dextroamphetamine in lower dosage also reduced disability by some 17 percent. The most disabled patients, including those also on levodopa, showed the greatest response to amphetamines. Previously, amphetamines have been reported to be a selective treatment for the oculogyric crises of post-encephalitic Parkinsonism...
March 1975: Journal of Neurology, Neurosurgery, and Psychiatry
M Campbell, A M Small, P J Collins, E Friedman, R David, N Genieser
No abstract text is available yet for this article.
January 1976: Current Therapeutic Research, Clinical and Experimental
L E Arnold, R D Huestis, D J Smeltzer, J Scheib, D Wemmer, G Colner
Double-blind crossover randomized Latin square comparison of placebo, dextroamphetamine, and levoamphetamine in 31 consecutively diagnosed children with minimal brain dysfunction (MBD) replicated a smaller nonrandom study. Both isomers showed significantly more benefit than placebo but were not significantly different from each other. Dextroamphetamine showed a nonsignificant trend of superiority over levoamphetamine. Of 25 subjects who responded well to drugs, three responded only to levoamphetamine, five only to dextroamphetamine, and 17 to both...
March 1976: Archives of General Psychiatry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"